The Effectiveness And Safety Of Amisulpride In Chinese Patients With Schizophrenia: An 8-Week, Prospective, Open-Label, Multicenter, Single-Arm Study

Ying Liang,Changan Cao,Cheng Zhu,Chuanyue Wang,Congpei Zhang,Fang Dong,Fude Yang,Hong Deng,Jingjie Yu,Jisheng Tang,Lei Su,Limin Xin,Ling Hong,Minglong Gao,Muni Tang,Shiping Xie,Shuiping Lu,Tiebang Liu,Xiaojin Xu,Xijin Wang,Xuanzi Li,Xueyi Wang,Yi Li,Yong Zhang,Zhiyu Chen,Xin Yu
DOI: https://doi.org/10.1111/appy.12238
2016-01-01
Asia-Pacific Psychiatry
Abstract:Introduction: This study evaluated the effectiveness and safety of amisulpride in Chinese schizophrenia patients.Methods: A multicenter, single-arm Phase IV study (NCT01795183). Chinese patients with schizophrenia received amisulpride for 8weeks. The primary endpoint was >= 50% decrease in Positive and Negative Syndrome Scale total score from Baseline to Week 8.Results: A total of 316 patients were enrolled; 295 were included in the effectiveness analysis; 66.8% (197/ 295) achieved >= 50% decrease in Positive and Negative Syndrome Scale total score from Baseline to Week 8. Nine patients discontinued treatment because of adverse events.Discussion: Amisulpride had clinical effectiveness and was relatively well tolerated in Chinese patients with schizophrenia.
What problem does this paper attempt to address?